Return to News
10 May 2024
Tags: News Events Media

ZEPFHR-MM Receives MRFF Grant Funding

The Australasian Myeloma Research Consortium - AMaRC - is very excited to announce the awarding of funding for the ZEPFHR-MM study via the Medical Research Future Fund - Clinical Trials Activity Grant Opportunity. The funding amount allocated is over $3,400,000 AUD.

The ZEPFHR-MM trial is a world-first, international collaboration, platform study exploring novel treatments for multiple myeloma (MM) patients with the shortest survival - Functional High-Risk MM (FHR), incorporating an extensive international correlative research effort to further understand FHR MM. Operating under a centralised HREC approval and master protocol, the ZEPFHR-MM trial will allow:

  • Multiple study domains (analogous to multiple study arms) to open simultaneously and allow rapid identification of novel drug combinations with promising efficacy against FHR MM.
  • Participating sites to tailor treatment to suit their capabilities and patient population needs by choosing to participate in their preferred domains.
  • Entrenchment of multi-site standardised Minimal Residual Disease (MRD) testing across all domains.


ZEPFHR-MM & The AMaRC Correlatives Network

The ZEPFHR-MM will incorporate a suite of correlative research platforms including genomics, transcriptomics, metabolomics, proteomics, immune profiling and biobanking. This is the first collaborative project leveraging the AMaRC Correlatives Network, an international alliance of correlative research experts capable of maximising the scientific value of the ZEPFHR-MM and our understanding of multiple myeloma. We are excited to be collaborating with experts from the following institutions:

  • Australian Centre for Blood Diseases, Monash University, Melbourne
  • Fred Hutchinson Cancer Center, Seattle, USA
  • National University of Singapore, Singapore
  • Children's Medical Research Institute, Sydney
  • Royal Prince Alfred Hospital, Sydney
  • St Vincent’s Hospital Melbourne, Melbourne
  • Peter MacCallum Cancer Centre, Melbourne
  • University of Otago, Otago, New Zealand
  • University of Western Australia, Perth
  • University of Adelaide, Adelaide

The ZEPFHR-MM trial will begin seeking expression of interested from hospital sites, with the hopes of opening late 2024.